Cellumed Begins Development of Next-Generation Peptide-Based Bone Graft Materials Using AI Technology

Cellumed, a specialized manufacturer of bio-medical devices, announced on July 22 that it has officially begun development of next-generation peptide-based bone graft materials utilizing the AI-powered protein structure prediction program 'AlphaFold 3'.

Currently, Cellumed's main products are 'Rafugen DBM (Demineralized Bone Matrix)' for orthopedic use and 'Rafugen Dental' for dental applications. For bone graft materials, osteogenic capability and biocompatibility (the property of not causing adverse reactions with human tissue) are key elements. The company plans to further enhance both elements through new peptide bonding technologies. In particular, from the early stages of development, Cellumed has focused on expanding indications to address a wide range of clinical needs, such as bone reconstruction after cancer surgery, beyond the existing indications.

This development actively leverages Cellumed's more than 20 years of accumulated experience in protein research and manufacturing know-how. Cellumed has already independently developed and successfully mass-produced the fibroblast growth factor FGF7. This substance has been applied to InskoBi's 'Dermicos' cosmetics brand, demonstrating anti-aging effects. According to the company, FGF7 has also been proven through SCI-level papers to be effective in skin aging management and wound healing, raising its potential for medical applications.

AlphaFold 3, which is being used for the development of next-generation bone graft materials, is a state-of-the-art artificial intelligence technology developed by Google DeepMind that can predict the three-dimensional structure of proteins with much higher accuracy than before. Previously, peptide bonding and evaluation processes took two to three years, but Cellumed plans to significantly reduce development time by adopting AlphaFold 3.

A Cellumed representative stated, "Based on the needs of the medical community, we have been preparing to develop next-generation bone graft materials with a primary focus on improving osteogenic capability and biocompatibility," and added, "By combining the technological capabilities of AlphaFold 3 with our expertise in protein development, we expect to reduce trial and error in the development process and accelerate the timeline for commercialization."

This content was produced with the assistance of AI translation services.